Bristol-Myers Squibb Company (BMY) debt
What Bristol-Myers Squibb owes, when it comes due, and what it costs to carry, from the balances and cash flows the company reports to the U.S. Securities and Exchange Commission.
At a glance
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Total debt | $42.62B | $48.72B | −$6.10B |
| Due within a year | $1.03B | $4.51B | −$3.48B |
| Long-term debt | $41.85B | $44.47B | −$2.62B |
| Cash and equivalents | $9.57B | $15.73B | −$6.15B |
| Net debt | $33.04B | $32.99B | +$52M |
Debt over time
| Balance date | Total debt | Due within a year | Long-term debt | Cash |
|---|---|---|---|---|
| Sep 2026 | $42.62B | $1.03B | $41.85B | $9.57B |
| Jun 2026 | $42.86B | $1.03B | $42.09B | $8.72B |
| Mar 2026 | $44.14B | $2.31B | $42.15B | $9.57B |
| Dec 2025 | $44.83B | $2.26B | $42.85B | $10.21B |
| Sep 2025 | $48.72B | $4.51B | $44.47B | $15.73B |
| Jun 2025 | $48.95B | $4.71B | $44.47B | $12.60B |
| Mar 2025 | $49.51B | $3.55B | $46.16B | $10.88B |
| Dec 2024 | $49.43B | $2.05B | $47.60B | $10.35B |
| Sep 2024 | $49.55B | $1.08B | $48.67B | $7.89B |
| Jun 2024 | $51.95B | $3.53B | $48.86B | $6.29B |
| Mar 2024 | $55.68B† | $6.19B | $49.49B | $9.33B |
| Dec 2023 | $39.53B | $3.12B | $36.65B | $11.46B |
† Sum of the debt lines the company reports at that date, not a reported total.
When it comes due
Principal due by year as of December 31, 2025.
| Due | Principal | Share of total |
|---|---|---|
| Within 1 year | $2.00B | 22.6% |
| Year 2 | $2.00B | 22.6% |
| Year 3 | $544M | 6.2% |
| Year 4 | $2.20B | 24.9% |
| Year 5 | $2.10B | 23.7% |
| Total | $8.84B | 100% |
Interest cost and borrowing
| Fiscal year | Interest expense | Borrowed | Repaid |
|---|---|---|---|
| FY Dec 2025 | $1.89B | $5.74B | $10.94B |
| FY Dec 2024 | $1.95B | $12.88B | $2.87B |
| FY Dec 2023 | $1.17B | $4.46B | $3.88B |
| FY Dec 2022 | $1.23B | $5.93B | $11.43B |
| FY Dec 2021 | $1.33B | $0 | $6.02B |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters.
About these figures
These are the balances Bristol-Myers Squibb reports in its SEC filings as of each balance-sheet date, and the interest, borrowing and repayments it reports for each period. This page does not show market prices or yields of the company's bonds. "Long-term debt" is the line as the company tags it in its filings and may or may not include the portion due within a year.
All figures from company filings with the SEC.